The company has pivoted to serve the research market but still hopes to spearhead translation of immunotherapy biomarkers following CLIA validation of its approach.
Cofactor's kit will be used to characterize the immune responses generated in reaction to treatment with an investigational personalized cancer vaccine.
St. Louis-based Cofactor will use the National Cancer Institute's clinical specimens in order to validate its Paragon assay platform.
Researchers who used the company's service presented data this week from analyses of sarcoma patients that they believe can help personalize care.
The financing follows Cofactor's launch of Pinnacle, an RNA-based oncology assay and the company's first product since a strategic refocusing.
The Pinnacle assay for gene fusions and gene expression in tumor samples is the first in Cofactor's new line of clinical RNA-sequencing assays.
The platform will be designed to gather all necessary data from a single RNA extraction, eliminating the need for flow cytometry, genomic sequencing, and expression profiling.
The companies will combine Cofactor's RNA-seq know-how with SII's big data analytics offerings to provide services for pharmaceutical research customers.
The RNA products developer is buying California-based Narus in order to expand into the RNA-based diagnostics market.
The company aims to use the funding to further optimize the technology and support an ongoing early-access program with beta testers.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.